Phase I–II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin–cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma

Author： Andreopoulou Eleni   Vigoda Ivette   Valero Vicente   Hershman Dawn   Raptis George   Vahdat Linda   Han Hyo   Wright John   Pellegrino Christine   Cristofanilli Massimo   Alvarez Ricardo   Fehn Karen   Fineberg Susan   Sparano Joseph  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.141, Iss.3, 2013-10, pp. : 429-435

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines

By Ellis C.A.  

Breast Cancer Research and Treatment, Vol. 78, Iss. 1, 2003-03 ,pp. : 59-67

Springer Publishing Company

Access to resources Recommend Favorite

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

By Kerklaan Bojana   Diéras Veronique   Tourneau Christophe   Mergui-Roelvink Marja   Huitema Alwin   Rosing Hilde   Beijnen Jos   Marreaud Sandrine   Govaerts Anne-Sophie   Piccart-Gebhart Martine   Schellens Jan   Awada Ahmad  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 53-62

Springer Publishing Company

Access to resources Recommend Favorite

Two Sequential Studies for Primary Peritoneal Carcinoma: Induction with Weekly Cisplatin Followed by either Cisplatin-Doxorubicin-Cyclophosphamide or Paclitaxel-Cisplatin

By Piver M.S.   Eltabbakh G.H.   Hempling R.E.   Recio F.O.   Blumenson L.E.  

Gynecologic Oncology, Vol. 67, Iss. 2, 1997-11 ,pp. : 141-146

Elsevier

Access to resources Recommend Favorite

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

By Livingston Robert   Barlow William   Kash Joseph   Albain Kathy   Gralow Julie   Lew Danika   Flaherty Lawrence   Royce Melanie   Hortobagyi Gabriel  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 123-131

Springer Publishing Company

Access to resources Recommend Favorite